(Q38230163)

31 August 2017

title

Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use. (English)

1 reference

inflammatory bowel diseases

31 August 2017

main subject

0 references

author name string

Hiroshi Nakase

series ordinal

1

1 reference

31 August 2017

Takuya Yoshino

series ordinal

2

1 reference

31 August 2017

Minoru Matsuura

series ordinal

3

1 reference

31 August 2017

publication date

1 November 2014

1 reference

Inflammatory Bowel Diseases

31 August 2017

published in

1 reference

31 August 2017

volume

20

1 reference

31 August 2017

issue

11

1 reference

31 August 2017

page(s)

2151-2156

1 reference

Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Biological effects of cyclosporin A: A new antilymphocytic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Phosphorylation of the Transcription Factor NFATp Inhibits Its DNA Binding Activity in Cyclosporin A-treated Human B and T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Requirement for transcription factor NFAT in interleukin-2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

NFAT control of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Optimization of the use of Calcineurin inhibitors in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Calcineurin inhibitors: 40 years later, can't live without ...

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Treatment of choice for acute severe steroid-refractory ulcerative colitis is cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Therapeutic drug monitoring for immunosuppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Use of tacrolimus in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Response of refractory colitis to intravenous or oral tacrolimus (FK506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Novel targets for inflammatory bowel disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Systematic review: the role of tacrolimus in the management of Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0000000000000130

10.1097/MIB.0000000000000130

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference